Harnessing the power of state-of-the-art technology and “big data” analysis, researchers at the newly formed Arizona COVID-19 Genomics Union (ACGU) seek to better understand how this virus may be evolving, how it is transmitted and how it is moving through the general population.
The antibody tests build upon the work of UArizona Health Sciences and BIO5 Institute researchers. The tests will help determine how many people have been exposed to the novel coronavirus and have successfully built an immunity against it.
Audiologist and molecular biologist O’neil Guthrie, an associate professor in Northern Arizona University’s Department of Communication Sciences and Disorders, is collaborating with New Jersey-based Optigenex to conduct a pre-clinical investigation to help the body’s natural ability to repair DNA through
a novel therapy.
On the heels of a study showing how cancer can be precisely detected by a liquid biopsy blood test created by the Translational Genomics Research Institute (TGen), a new $2.1 million federal grant will enable TGen and Mayo Clinic researchers to fine-tune the system in clinical trials.
Scientists develop new approach to treat wounds by using three-dimensional skin substitutes formed from native skin proteins through a process called electrospinning. Shifting from using synthetic materials, electrospun
protein scaffolds guide cell adhesion and growth, and can be used to deliver cells, drugs and even genes into the body.
Rosalind Sadleir, an associate professor of biomedical engineering in the Ira A. Fulton Schools of Engineering at Arizona State University, is working to measure electrical properties of different types of tissue to better capture what’s happening in the body and better diagnose patients.
Researchers have found that a gene known as AEBP1 may play a central role in the development, severity and potential treatment of liver disease
A new type of blood test for breast cancer could help avoid thousands of unnecessary surgeries and otherwise precisely monitor disease progression
While family history has previously been associated with the risk of Alzheimer’s, this is the first study of its kind that in these numbers indicates the risk can be detected up to four decades before the typical age of onset.
While the sequencing of hundreds of thousands of human cancer genomes has driven the transformational development of precise targeted cancer treatments for humans over the past decade, relatively few canine cancer genomes have undergone similar profiling. The canine cancer genomic discovery and drug development efforts of the TGen-Ohio State team are pieces of a larger puzzle that could similarly transform veterinary oncology, while creating bridges between canine and human cancer drug development.